Comparison of efficacy of rifaximin, probiotics and L-ornithine L-aspartate in overt hepatic encephalopathy: a randomized, phase IV, lactulose controlled clinical trial. [PDF]
TrialsShahbaz A +5 more
europepmc +1 more source
Effects of rifaximin in fructose-induced steatohepatitis in rats. [PDF]
Hepatol ForumCelik NC +6 more
europepmc +1 more source
Severe Hyperammonemic Encephalopathy Associated With Gastrointestinal Bleeding During Capecitabine and Oxaliplatin Chemotherapy in a Patient With Rectal Adenocarcinoma. [PDF]
CureusKomatsu T, Agrawal VA.
europepmc +1 more source
Rifaximin reduces gut-derived inflammation in severe acute pancreatitis: an experimental animal model and randomized controlled trial. [PDF]
Microbiol SpectrZou Y-y +13 more
europepmc +1 more source
Rifaximin and sarcopenia in cirrhosis: Commentary on a promising but complex relationship. [PDF]
World J HepatolEl-Kassas M, AlNaamani K.
europepmc +1 more source
Difficulties in diagnosing a pediatric patient with small intestinal bacterial overgrowth. [PDF]
Einstein (Sao Paulo)Tuñas LC +3 more
europepmc +1 more source
Related searches:
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J. Cada +2 more
+4 more sources
Rifaximin has the potential to prevent complications of cirrhosis [PDF]
Therapeutic Advances in Gastroenterology, 2018 Background: Cirrhosis-related complications are associated with poor prognosis. With our analyses, we examined the potential benefit of rifaximin in reducing the risk of developing cirrhosis-related complications.
Steven L Flamm +2 more
exaly +3 more sources